CA2304949A1 - Diagnostic test for alzheimer's disease - Google Patents
Diagnostic test for alzheimer's disease Download PDFInfo
- Publication number
- CA2304949A1 CA2304949A1 CA002304949A CA2304949A CA2304949A1 CA 2304949 A1 CA2304949 A1 CA 2304949A1 CA 002304949 A CA002304949 A CA 002304949A CA 2304949 A CA2304949 A CA 2304949A CA 2304949 A1 CA2304949 A1 CA 2304949A1
- Authority
- CA
- Canada
- Prior art keywords
- ache
- glycosylation pattern
- csf
- isoform
- alzheimer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 135
- 238000002405 diagnostic procedure Methods 0.000 title description 6
- 108010022752 Acetylcholinesterase Proteins 0.000 claims abstract description 200
- 229940022698 acetylcholinesterase Drugs 0.000 claims abstract description 195
- 230000013595 glycosylation Effects 0.000 claims abstract description 45
- 238000006206 glycosylation reaction Methods 0.000 claims abstract description 45
- 108010062580 Concanavalin A Proteins 0.000 claims abstract description 31
- 238000000034 method Methods 0.000 claims abstract description 26
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 claims abstract description 18
- 210000001124 body fluid Anatomy 0.000 claims abstract description 9
- 239000010839 body fluid Substances 0.000 claims abstract description 9
- 238000003745 diagnosis Methods 0.000 claims abstract description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 claims description 195
- 102000001708 Protein Isoforms Human genes 0.000 claims description 69
- 108010029485 Protein Isoforms Proteins 0.000 claims description 69
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 69
- 230000000694 effects Effects 0.000 claims description 48
- 239000002523 lectin Substances 0.000 claims description 22
- 108090001090 Lectins Proteins 0.000 claims description 20
- 102000004856 Lectins Human genes 0.000 claims description 20
- 102100032404 Cholinesterase Human genes 0.000 claims description 19
- 238000004458 analytical method Methods 0.000 claims description 18
- 108010053652 Butyrylcholinesterase Proteins 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 210000002381 plasma Anatomy 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 238000005259 measurement Methods 0.000 claims description 3
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 abstract description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 abstract 5
- 210000005153 frontal cortex Anatomy 0.000 description 33
- 210000004556 brain Anatomy 0.000 description 25
- 210000001638 cerebellum Anatomy 0.000 description 24
- 206010012289 Dementia Diseases 0.000 description 22
- 208000012902 Nervous system disease Diseases 0.000 description 20
- 208000025966 Neurological disease Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
- 238000004062 sedimentation Methods 0.000 description 14
- 108090000322 Cholinesterases Proteins 0.000 description 12
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 9
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 9
- 230000002547 anomalous effect Effects 0.000 description 9
- 239000005720 sucrose Substances 0.000 description 9
- 229920000936 Agarose Polymers 0.000 description 8
- 208000037259 Amyloid Plaque Diseases 0.000 description 8
- 229920002684 Sepharose Polymers 0.000 description 8
- 230000003247 decreasing effect Effects 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 108090000623 proteins and genes Proteins 0.000 description 8
- 238000000692 Student's t-test Methods 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 102000003914 Cholinesterases Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 229940048961 cholinesterase Drugs 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 102000016938 Catalase Human genes 0.000 description 5
- 108010053835 Catalase Proteins 0.000 description 5
- 230000002490 cerebral effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 5
- 230000002861 ventricular Effects 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 210000001652 frontal lobe Anatomy 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- QYOVMAREBTZLBT-KTKRTIGZSA-N CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO QYOVMAREBTZLBT-KTKRTIGZSA-N 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 102000014303 Amyloid beta-Protein Precursor Human genes 0.000 description 2
- 108010079054 Amyloid beta-Protein Precursor Proteins 0.000 description 2
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 2
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 2
- IOIMDJXKIMCMIG-UHFFFAOYSA-N Diphosphoramide, N,N',N'',N'''-tetrakis(1-methylethyl)- Chemical compound CC(C)NP(=O)(NC(C)C)OP(=O)(NC(C)C)NC(C)C IOIMDJXKIMCMIG-UHFFFAOYSA-N 0.000 description 2
- 101001078093 Homo sapiens Reticulocalbin-1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 102100025335 Reticulocalbin-1 Human genes 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 239000000910 agglutinin Substances 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 210000004900 c-terminal fragment Anatomy 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000001320 hippocampus Anatomy 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 1
- NTBLZMAMTZXLBP-UHFFFAOYSA-M 2-acetylsulfanylethyl(trimethyl)azanium;iodide Chemical compound [I-].CC(=O)SCC[N+](C)(C)C NTBLZMAMTZXLBP-UHFFFAOYSA-M 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 101100309447 Caenorhabditis elegans sad-1 gene Proteins 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 108010058699 Choline O-acetyltransferase Proteins 0.000 description 1
- 102100023460 Choline O-acetyltransferase Human genes 0.000 description 1
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Chemical group CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- 241001634308 Dolichus Species 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102100021238 Dynamin-2 Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 201000009051 Embryonal Carcinoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Chemical group C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 101000817607 Homo sapiens Dynamin-2 Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical group CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 235000003846 Ricinus Nutrition 0.000 description 1
- 241000322381 Ricinus <louse> Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 240000003864 Ulex europaeus Species 0.000 description 1
- 235000010730 Ulex europaeus Nutrition 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 1
- 239000003150 biochemical marker Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 229940021260 by ache Drugs 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000001353 entorhinal cortex Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000004558 lewy body Anatomy 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000007491 morphometric analysis Methods 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 230000001423 neocortical effect Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000001722 neurochemical effect Effects 0.000 description 1
- 230000007138 neurofibrillary change Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 238000000856 sucrose gradient centrifugation Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 210000002222 superior cervical ganglion Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- YLJREFDVOIBQDA-UHFFFAOYSA-N tacrine Chemical compound C1=CC=C2C(N)=C(CCCC3)C3=NC2=C1 YLJREFDVOIBQDA-UHFFFAOYSA-N 0.000 description 1
- 229960001685 tacrine Drugs 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/18—Carboxylic ester hydrolases (3.1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/827—Actinoplanes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO9432A AUPO943297A0 (en) | 1997-09-24 | 1997-09-24 | Diagnostic test for alzheimer's disease |
| AUPO9432 | 1997-09-24 | ||
| PCT/AU1998/000809 WO1999015695A1 (en) | 1997-09-24 | 1998-09-24 | Diagnostic test for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2304949A1 true CA2304949A1 (en) | 1999-04-01 |
Family
ID=3803714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002304949A Abandoned CA2304949A1 (en) | 1997-09-24 | 1998-09-24 | Diagnostic test for alzheimer's disease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6461831B1 (https=) |
| EP (1) | EP1017845B1 (https=) |
| JP (1) | JP2001517456A (https=) |
| AT (1) | ATE323781T1 (https=) |
| AU (1) | AUPO943297A0 (https=) |
| BR (1) | BR9813015A (https=) |
| CA (1) | CA2304949A1 (https=) |
| DE (1) | DE69834263D1 (https=) |
| HU (1) | HUP0003684A3 (https=) |
| IL (1) | IL135211A0 (https=) |
| WO (1) | WO1999015695A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL130225A0 (en) | 1999-05-31 | 2000-06-01 | Yissum Res Dev Co | Novel uses of antibodies against ache and peptides thereof |
| US20020150878A1 (en) * | 2001-01-23 | 2002-10-17 | Small David Henry | Method for the diagnosis of Alzheimer's Disease and other prion related disorders |
| JP2006515927A (ja) * | 2002-12-20 | 2006-06-08 | モメンタ ファーマシューティカルズ インコーポレイテッド | 疾患を診断および監視するためのグリカンマーカー |
| GB2404734A (en) * | 2003-08-05 | 2005-02-09 | Secr Defence | A method of screening a sample for abnormally glycosylated and/or expressed proteins |
| US20060094064A1 (en) * | 2003-11-19 | 2006-05-04 | Sandip Ray | Methods and compositions for diagnosis, stratification, and monitoring of alzheimer's disease and other neurological disorders in body fluids |
| JP2007513337A (ja) * | 2003-11-19 | 2007-05-24 | サトリス， インコーポレイテッド | アルツハイマー病の診断方法、層化方法およびモニタリング方法 |
| US20050272643A1 (en) * | 2004-06-08 | 2005-12-08 | Windber Research Institute | Removal of serum albumin from human serum or plasma |
| US7851172B2 (en) | 2006-07-25 | 2010-12-14 | University Of Kentucky Research Foundation | Biomarkers of mild cognitive impairment and alzheimer's disease |
| US20100124756A1 (en) * | 2008-10-10 | 2010-05-20 | Sandip Ray | Collection of biomarkers for diagnosis and monitoring of alzheimer's disease in body fluids |
| US20110237537A1 (en) * | 2009-05-29 | 2011-09-29 | Lombard Jay L | Methods for assessment and treatment of mood disorders via single nucleotide polymorphisms analysis |
| US8355927B2 (en) | 2010-11-05 | 2013-01-15 | Genomind, Llc | Neuropsychiatric test reports |
| US9493834B2 (en) | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
| US20110202284A1 (en) * | 2010-02-10 | 2011-08-18 | Mcreynolds Cristopher | Novel groups of biomarkers for diagnosing alzheimer's disease |
| ES2395063B1 (es) * | 2011-03-04 | 2014-02-07 | Universidad Miguel Hernández De Elche | Método para determinar la enfermedad de Alzheimer mediante la detección de glicoproteínas portadoras del glicoepítopo HNK-1 |
| CA2877975C (en) | 2012-04-13 | 2021-09-21 | Oasis Diagnostics Corporation | Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595883A (en) * | 1990-06-01 | 1997-01-21 | E. R. Squibb & Sons, Inc. | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid |
| CA2048700A1 (en) | 1990-09-04 | 1992-03-05 | Dasakumar S. Navaratnam | Method for diagnosing senile dementia of the alzheimer type |
| US5200324A (en) * | 1990-09-04 | 1993-04-06 | E. R. Squibb & Sons, Inc. | Method of diagnosing senile dementia of the Alzheimer type |
-
1997
- 1997-09-24 AU AUPO9432A patent/AUPO943297A0/en not_active Abandoned
-
1998
- 1998-09-24 WO PCT/AU1998/000809 patent/WO1999015695A1/en not_active Ceased
- 1998-09-24 HU HU0003684A patent/HUP0003684A3/hu unknown
- 1998-09-24 AT AT98946146T patent/ATE323781T1/de not_active IP Right Cessation
- 1998-09-24 CA CA002304949A patent/CA2304949A1/en not_active Abandoned
- 1998-09-24 EP EP98946146A patent/EP1017845B1/en not_active Expired - Lifetime
- 1998-09-24 IL IL13521198A patent/IL135211A0/xx unknown
- 1998-09-24 DE DE69834263T patent/DE69834263D1/de not_active Expired - Lifetime
- 1998-09-24 US US09/509,203 patent/US6461831B1/en not_active Expired - Fee Related
- 1998-09-24 JP JP2000512983A patent/JP2001517456A/ja active Pending
- 1998-09-24 BR BR9813015-3A patent/BR9813015A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999015695A1 (en) | 1999-04-01 |
| ATE323781T1 (de) | 2006-05-15 |
| EP1017845B1 (en) | 2006-04-19 |
| EP1017845A1 (en) | 2000-07-12 |
| JP2001517456A (ja) | 2001-10-09 |
| HUP0003684A2 (hu) | 2001-02-28 |
| US6461831B1 (en) | 2002-10-08 |
| EP1017845A4 (en) | 2003-07-02 |
| DE69834263D1 (de) | 2006-05-24 |
| IL135211A0 (en) | 2001-05-20 |
| AUPO943297A0 (en) | 1997-10-16 |
| BR9813015A (pt) | 2000-08-15 |
| HUP0003684A3 (en) | 2003-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1017845B1 (en) | Diagnostic test for alzheimer's disease | |
| US20020022242A1 (en) | Diagnostic test for alzheimer's disease | |
| JP5668201B2 (ja) | スクリーニング方法 | |
| Inestrosa et al. | Acetylcholinesterase accelerates assembly of amyloid-β-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme | |
| Selcen et al. | Dok‐7 myasthenia: phenotypic and molecular genetic studies in 16 patients | |
| Svensson et al. | Characterization of muscarinic receptor subtypes in Alzheimer and control brain cortices by selective muscarinic antagonists | |
| Takahashi et al. | Aprataxin, causative gene product for EAOH/AOA1, repairs DNA single-strand breaks with damaged 3′-phosphate and 3′-phosphoglycolate ends | |
| US20130251731A1 (en) | Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies | |
| Nakano et al. | Acetylcholinesterase activity in cerebrospinal fluid of patients with Alzheimer's disease and senile dementia | |
| Tsuji et al. | Specific induction of macrophage inflammatory protein 1‐α in glial cells of Sandhoff disease model mice associated with accumulation of N‐acetylhexosaminyl glycoconjugates | |
| Liu et al. | A novel reciprocal and biphasic relationship between membrane cholesterol and β‐secretase activity in SH‐SY5Y cells and in human platelets | |
| Kagitani‐Shimono et al. | Lipocalin‐type prostaglandin D synthase (β‐trace) is upregulated in the αB‐crystallin‐positive oligodendrocytes and astrocytes in the chronic multiple sclerosis | |
| Jelic et al. | Abnormal platelet amyloid-β protein precursor (AβPP) metabolism in Alzheimer's disease: identification and characterization of a new AβPP isoform as potential biomarker | |
| US5595883A (en) | Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid | |
| Sirviö et al. | Cholinesterases in the cerebrospinal fluid, plasma, and erythrocytes of patients with Alzheimer's disease | |
| Silveyra et al. | Altered glycosylation of acetylcholinesterase in Creutzfeldt–Jakob disease | |
| Boopathy et al. | Aryl acylamidase activity on acetylcholinesterase is high during early chicken brain development | |
| Junco et al. | Protein kinase C V3 domain mutants with differential sensitivities to m‐calpain are not resistant to phorbol‐ester‐induced down‐regulation | |
| AU744215B2 (en) | Diagnostic test for Alzheimer's disease | |
| McGeer et al. | Angiotensin-converting enzyme in cortical tissue in Alzheimer's and some other neurological diseases | |
| MXPA00002858A (en) | Diagnostic test for alzheimer's disease | |
| CZ20001053A3 (cs) | Diagnostický test na Alzheimerovu chorobu | |
| KR20020021775A (ko) | 사포신 및 기타 마커를 사용하는 리소좀 축적 질환의 진단방법 | |
| WO2002018623A2 (en) | Methods and reagents for protease inhibition | |
| Chawla et al. | Genetic variants of Abo blood group and coronary artery disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |